Introduction
============

Acne vulgaris is a common and chronic disease, with a prevalence rate of 9.38% (male 8.96%, female 9.81%) worldwide in 2010, resulting in 7.2 years lived with "disability" from the Global Burden of Disease Study 2013.[@b1-ccid-12-151],[@b2-ccid-12-151] Acne vulgaris can cause myriads of problems, both physical and psychological, such as post-acne redness, post-inflammatory hyperpigmentation, hypertrophic or atrophic acne scars, as well as influencing quality-of-life.[@b3-ccid-12-151]--[@b6-ccid-12-151]

Topical retinoids are the mainstay in the maintenance phase of treatment and are also recommended to use as monotherapy in mild degree acne or in combination with antimicrobials in more severe disease. Retinoids increase epithelial turnover and have comedolytic and anti-inflammatory actions.[@b7-ccid-12-151] Nevertheless, "retinoid reactions" such as erythema, burning sensation, erythema, peeling, and retinoid dermatitis are well recognized.[@b8-ccid-12-151],[@b9-ccid-12-151]

Interestingly, the role of "dermocosmetics" is increasingly important, as many patients and even physicians now resort to them as first-line management in mild-to-moderate acne. This area of acne management is highly controversial, lacking strong evidence to support.[@b10-ccid-12-151],[@b11-ccid-12-151] The active ingredients in some products are designed to work on the four main pathogeneses.[@b10-ccid-12-151],[@b12-ccid-12-151],[@b13-ccid-12-151] There were many reports showing beneficial effects when combined with standard treatment, resulting in increased efficacy and decreased side effects,[@b14-ccid-12-151]--[@b16-ccid-12-151] whereas some reports showed no superiority of cosmeceutical product over standard medication.[@b17-ccid-12-151],[@b18-ccid-12-151]

As many physicians are reluctant to prescribe skin moisturizer when treating acne patients for fear of worsening the therapeutic outcome. The objective of this study was to determine whether a combination of cosmeceutical products with a retinoid, adapalene, would result in similar improvements in mild-to-moderate acnes compared with retinoid alone (a non-inferiority comparison). Our secondary objective was to test the ability of these active ingredients to reduce the side-effects of retinoids and to decrease complications of acne.

Materials and methods
=====================

This was a single center, double blinded split-face comparative study. The study was conducted from June 2017 through September 2017. This study was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University, Thailand, and was registered at Thai Clinical Trials Registry as a primary site, no. TCTR20171031005. This study was conducted in accordance with the Declaration of Helsinki. All participants provided informed consent before starting the study. Individual participant data of the study, after deidentification, is not being shared with others. We do not share any specific data, and no other study-related documents will be made available. Our patients' data were recorded in a case record form. The case record form and essential documents will be kept in a designated place for 15 years. The data and documents are available if requested by relevant authorities.

Study population
----------------

Female and male participants aged between 18--40 years old with clinically diagnosed mild-to-moderate degree facial acne vulgaris according to the Acne Consensus Conference (ACC)[@b19-ccid-12-151] were recruited. The participants were excluded if they used oral acne treatment within 4 weeks, topical treatment within 2 weeks, or light/laser therapy or oral treatment within 4 weeks. Participants who had any other dermatologic diseases in the study area were not eligible. Female participants with childbearing potential could not be pregnant during the study and were advised to use reliable contraceptive measures throughout the study period.

Treatment regimen
-----------------

Each participant received two kinds of products, which consisted of (1) active ingredients, namely glycolic acid 7%, salicylic acid 1%, gluconolactone 2.0%, licochalcone A 0.05%, mixed with adapalene 0.1% (Beiersdorf, Germany), and (2) the adapalene 0.1%. Each product was applied once daily on one side of the face at night in a quantity of a half fingertip unit (0.25 grams). All participants were provided with skin cleanser (Eucerin, Beiersdorf, Germany) for twice-daily use. The protocol was continued for 28 days with four visits, which were on days 0 (baseline), 7, 14, and 28. All skin assessments were measured at each visit. Participants were advised not to use new skin care products or other medications during the entire course of the study.

Efficacy assessment
-------------------

Efficacy for acne vulgaris was measured by counting of the acne lesions, which comprised comedones, inflammatory papules, and nodulocystic lesions, by the investigator (KK). The severity of acne vulgaris was graded as mild, moderate, or severe depending on the ACC.[@b19-ccid-12-151] Physician's global assessment (PGA) and patient's global assessment[@b20-ccid-12-151] (PaGA) were evaluated for each hemi-side at every visit. Responses for PGA and PaGA were 5-point Likert scales, where 0 refers to clear, residual hyperpigmentation and erythema; a response of 1 means almost clear of skin lesions, a few scattered comedones, and a few small papules; 2 suggests a mild degree, easy to recognize; 3 refers to moderate degree acne, many comedones, papules, and pustules; and a response of 4 suggests severe degree acne, all of the area covered with comedones, numerous papules, and pustules (a few nodules and cysts may also be present).

Efficacies regarding skin brightening and radiance were evaluated on each hemi-side at every visit by subjects, using the visual analog scale (VAS), a subjective measurement, which is a 10 centimeters (100 millimeters) horizontal line. The subjects were asked to mark on the line what they thought represented their score. The minimum score is 0 (no radiance at all) and the maximum score is 100 (most radiant).

Safety assessment
-----------------

At study visits on days 7, 14, and 28, all subjects evaluated the safety from each treatment. Subjects would score each hemi-side with regards to erythema, burning sensation, and itch sensation (a 4-point Likert Scale; 0 = no, 1 = mild, 2 = moderate, 3 = severe). Similarly, the investigator (KK) also evaluated the safety profile by physical examination at the treated area in each hemi-side, then scored erythema on a 4-Likert scale; 0 = no, 1 = mild, 2 = moderate, 3 = severe.

Skin biophysical properties assessment
--------------------------------------

Before evaluation at each visit, the subjects would wash the face and rest for 10--15 minutes. The following biophysical properties were measured; first, the water content of the stratum corneum with Corneometer^®^ CM 825 (Courage-Khazaka, Cologne, Germany) and, second, the transepidermal water loss with Tewameter^®^ TM 300 (Courage-Khazaka) at days 0, 7, 14, and 28. The corneometer scores are presented as arbitrary Corneometer^®^ units (0--120) and the Tewameter measured in g/m^2^/h. These measurements were performed in a temperature- and humidity-controlled room (72.56±6.34°C and 21.58%±1.31% humidity). We located the site to measurement at 3 centimeters lateral to the lateral rim of alar nasi, horizontally. All measurements were done in triplicate, and the mean values were calculated.

Photographic assessment
-----------------------

At all visits, digital photographs were taken by the Visia^®^ camera system (software version 6.4.2, Canfield Scientific, Parsippany, NJ, US). The Visia system is a standardized photographic method with left, center, and right images. The system can detect spots, red areas, as a feature, showing an absolute score in a selected area ("mask" area), as well as auto-mask the same area at other visits. The cheek area in each hemi-side was used to compare the efficacy of the treatment.

To evaluate the spots and red area, the software can measure the "absolute scores", which are appropriate to use for comparison. They represent the fractional area of each skin feature relative to the area masked. The higher the score, the less problems the subjects have.

Outcome
-------

The primary efficacy outcome was the reduction of inflammatory lesions between two treatments at day 7 by using non-inferiority comparison.

The secondary outcomes were the reduction of inflammatory lesions between two treatments at day 28, and the side-effects of the two treatments, such as burning sensation, erythema, scaling, and acne complication, such as post-acne erythema and post-inflammatory hyperpigmentation. The differences in VISIA spot and red areas between the treatments were considered.

Statistical analyses
--------------------

The subject's demographic data, such as age, gender, weight, and height, were reported as mean and SD or percentage. Baseline demographic characteristics were compared between treatment groups using Student's *t*-test or chi-squared test. The number of comedones, inflammatory papules, nodulocystic acne, and inflammatory lesions (inflammatory papules add nodulocystic acne) in each hemi-side at each visit were reported as mean and SD, as well as the severity of acne vulgaris. Visual analog radiance score, skin biophysics, and adverse effects were shown as mean and SD.

For primary outcome, we set the non-inferiority margin at --1, assuming that the lower bound of the 90% CI of mean difference of inflammatory lesions between the control and treated groups was not less than (or smaller than) --1 unit. With a power of 80% and a one-sided significant level of 0.05, a sample size of 25 participants was needed after adjusting for a dropout rate at day 28 of 10%.

Comparisons of efficacy assessment, safety assessment, skin biophysical properties assessment, and photographic assessment between a cosmeceutical product mixed with 0.1% adapalene and 0.1% adapalene groups over the follow-up period of 28 days were conducted using a linear mixed-effect model with patients as a random effect. The comparisons of Visia spot count and red area feature count were analyzed by a Poisson regression mixed model.

All data management and analyses were conducted with R statistical software R version 3.4.1,[@b21-ccid-12-151] with the following packages: lme4, effects, and emmeans. In addition to non-inferiority analysis, all other statistical analysis was conducted with the significant levels of 0.05.

Results
=======

A total number of 32 subjects were screened. Four subjects were excluded due to severe acne vulgaris, and three subjects were not able to follow the study protocol. Consequently, the total number of the subjects was 25 ([Figure 1](#f1-ccid-12-151){ref-type="fig"}). Baseline characteristics of the study population are shown in [Table 1](#t1-ccid-12-151){ref-type="table"}. The average age was 24.32±5.76 years; participants were 80% female and 20% male. The number of acne lesions, severity of acne vulgaris, PGA, PaGA, VAS, and skin biophysics compared each hemi-side are shown in [Table 1](#t1-ccid-12-151){ref-type="table"}.

Patients' baseline demographics, clinical characteristic and skin biophysical properties among two treatment sides did not show statistically significant differences.

Efficacy assessment
-------------------

### Comedones

The observed comedones counts at baseline, days 7, 14, and 28 are shown in [Figure 2](#f2-ccid-12-151){ref-type="fig"}. At days 7 and 14, the number of comedones decreased from baseline, but they were increased at day 28. The comedones counts between the two groups were not statistically significantly different over time.

### Inflammatory lesions

The observed inflammatory lesions (inflammatory papules and nodulocystic lesion) counts at days 7, 14, and 28 are also shown in [Figure 2](#f2-ccid-12-151){ref-type="fig"}.

At day 7, inflammatory lesions decreased on the side receiving the active ingredients with adapalene more than the adapalene monotherapy, but they were increased at day 14. However, at day 28, both groups have comparable inflammatory lesion counts. There were no significant changes in inflammatory lesions at all the time points between the two groups.

For the primary outcome, the mean differences of inflammatory lesions reduction at day 7 between two groups was 0.391 (90% CI=0.253--0.530; [Figure 3](#f3-ccid-12-151){ref-type="fig"}). The lower confidence intervals of the mean differences between the two groups for every follow-up time did not exceed the non-inferiority margin of --1 ([Figure 3](#f3-ccid-12-151){ref-type="fig"}).

The mean differences of inflammatory lesions reduction between both groups at days 14 and 28 were −0.320 (90% CI=−0.454--0.185) and 0.333 (90% CI=0.222--0.466), respectively. The data are also shown in [Figure 3](#f3-ccid-12-151){ref-type="fig"}. The treatment result is illustrated in [Figure 4](#f4-ccid-12-151){ref-type="fig"}.

### Severity of acne

The severity of acne evaluated by ACC in both groups were decreased continuously at days 7, 14, and 28 from baseline. In the same way, PGA and PaGA showed that both treatments had similar improvement at days 7, 14, and 28 from baseline ([Table 2](#t2-ccid-12-151){ref-type="table"}). However, we could not find statistically significant differences in the severity of acne, PGA, and PaGA among the two groups.

### Efficacy for brightening and RADIANCE skin

Skin brightening and radiance skin measured through the visual analog scale were increasing from the baseline in both groups. However, we could not find a statistically significant difference between both groups at days 7, 14, and 28.

Safety assessment
-----------------

At all study visits (days 7, 14, and 28), the safety profile of both groups, defined as the average score of erythema and scaling, were evaluated by subjects and the investigator (KK). Most of the patients reported erythema and a scaling score ≤2, which means none reported severe symptoms. The erythema and scaling score from both patients and physician between the two treatments were not statistically significantly different at days 7, 14, and 28.

Moreover, we also evaluated the worst symptoms from the patients, defined as pruritus and burning sensation, at days 7, 14, and 28. Almost all of the patients reported pruritus sensation as "0=none" on both treatments, which was not significantly different. For the burning sensation, the patients reported a burning sensation on active ingredient with the adapalene side more than the adapalene alone side at days 7, 14, and 28. The mean score for the treatment group was significantly higher than control at day 7 ($\overline{X} = 1.234$, 95% CI=0.962--1.507 vs $\overline{X} = 0.495$, 95% CI=0.223--0.767), day 14 ($\overline{X} = 1.300$, 95% CI=0.767--1.833 vs $\overline{X} = 0.320$, 95% CI=0.058--0.582), and day 28 ($\overline{X} = 0.960$, 95% CI=0.698--1.222 vs $\overline{X} = 0.160$, 95% CI=−0.102--0.422) ([Table 3](#t3-ccid-12-151){ref-type="table"}).

Skin biophysical properties assessment
--------------------------------------

The skin hydration (Corneometer) was increased from baseline in both treatment groups at days 7, 14, and 28, but it showed no statistically significant differences among the two treatment groups. The transepidermal water loss (TEWL) of both treatment groups decreased from baseline at days 7 and 14 and slightly increased at day 28. However, we could not find statistically significant differences between the two treatment groups ([Table 2](#t2-ccid-12-151){ref-type="table"}).

Photographic assessment
-----------------------

The Visia "spots" absolute score for treatment group was significantly higher than control at day 7 ($\overline{X} = 48.117$, 95% CI=44.070--52.165 vs $\overline{X} = 45.769$, 95% CI=41.722--49.817), day 14 ($\overline{X} = 46.709$, 95% CI=42.687--50.730 vs $\overline{X} = 44.361$, 95% CI=40.339--48.383), and day 28 ($\overline{X} = 47.639$, 95% CI=43.617--51.660 vs $\overline{X} = 45.291$, 95% CI=41.267--49.313) from baseline ([Table 3](#t3-ccid-12-151){ref-type="table"}).

Although the Visia "red area" absolute score in both treatment groups was increased from baseline at days 7 and 14 and slightly decreased at day 28, it showed no statistically significant difference between the groups in any follow-up visits.

Discussion
==========

There are many external factors which affect the result of acne treatment, such as skin care, moisture, cosmeceutical, cleanser, and exposome. The cosmeceutical products have increasing roles in acne treatment and maintenance therapy.

The combination of our study product (active ingredients of glycolic acid, salicylic acid, gluconolactone, and licochalcone A) with adapalene was non-inferior to adapalene monotherapy with respect to inflammatory lesions. Most adverse effects were similar on both sides, although slightly more burning was reported on the combination side.

The results on redness as measured by the Visia system were not different between both sides. Of note, the results on spots as measured by the Visia system were better on the combination side. These measurements could be more efficient that the human eyes and tend to be more objective.

Adapalene, a third generation synthetic retinoid, has high affinity to retinoic acid receptor (RAR) β and γ. It has an anti-inflammatory effect due to it inhibiting the arachidonic acid via the lipoxygenase pathway and decreasing toll-like receptor 2 (TLR-2) expression in epidermal keratinocytes.[@b22-ccid-12-151]--[@b24-ccid-12-151]

Our result showed decreased comedones in both groups. Apart from the adapalene effects, our active ingredients are comprised of glycolic acid 7%, salicylic acid 1%, and gluconolactone 2%. The glycolic acid is an alpha-hydroxy acid (AHA) that can be used in all Fitzpatrick skin types. Of note is that a low concentration (2--5%) of glycolic acid disrupts the intercellular cohesiveness in the stratum corneum, resulting in normal epidermal keratinization. It also increases skin thickness within the epidermis and papillary dermis.[@b25-ccid-12-151],[@b26-ccid-12-151] Salicylic acid is a beta-hydroxy acid, which has action to normal keratinization, decreases inflammation, and reduces sebum production with a comedolytic effect. The concentration of salicylic to treat acne is 0.5--5%.[@b11-ccid-12-151],[@b27-ccid-12-151] Gluconolactone, an alpha-hydroxy acid, affects keratinization and reduces inflammatory lesions. Moreover, it has less side-effects than benzoyl peroxide.[@b28-ccid-12-151]

Apart from comedones, our study has demonstrated that both treatments could reduce inflammatory lesions from baseline. Licochalcone A, extracted from *Glycyrrhiza inflata*, has an anti-inflammatory effect with inhibition of prostaglandins synthesis. It has an effect both in *in vitro* and *in vivo* studies.[@b29-ccid-12-151]--[@b31-ccid-12-151] Licochalcone A has benefits on sensitive facial skin, rosacea, atopic dermatitis, seborrheic dermatitis, and acne.[@b32-ccid-12-151]--[@b36-ccid-12-151]

Adapalene has very little skin irritations, ie, no more than white petrolatum.[@b37-ccid-12-151],[@b38-ccid-12-151] This can be the explanation of why the difference of skin biophysical properties between the two groups were not observed. Moisturizer or cosmeceutical products should help minimize the side-effects of retinoids.[@b39-ccid-12-151] Similar to what was demonstrated by Chularojanamontri *et al*,[@b16-ccid-12-151] the skin hydration and transepidermal water loss were not statistically significantly different between adapalene plus active formulation and adapalene alone. They demonstrated that the addition of concomitant moisturizer to adapalene does not interfere with therapeutic effect. It was also demonstrated that the combination of adapalene with moisturizer resulted in slightly more pruritus and burning sensation at day 7.[@b40-ccid-12-151] These observations were in line with our study.

The strengths of our study are its good protocol compliance, with only one patient missing a visit, and consistency of assessment by the same investigators, as well as comprehensive (both subjective and objective) evaluations of the safety profile of treatment. The compounding of moisturizer with adapalene in one tube enhances ease of applications, while ensuring blinding of the study products.

Limitations include the use of adapalene as the main acne treatment. The results may not be applicable to other anti-acne preparations. Only 20% of our subjects were male. Whether both genders would respond similarly is questionable. Also, the total study period was 28 days, some additional benefits may be seen if the follow-up time was longer.

Conclusion
==========

As commonly known, the effects from cosmeceuticals were not obviously to surpass the standard treatment in acne. This study showed that addition of cosmeceuticals to adapalene had no benefits over adapalene alone in the view of treatment. However, it has benefits upon side-effects. Our results showed no hindrance of using a cosmeceutical combined with standard treatment. In future studies, use of other acne medications, the maintenance effect from cosmeceutical products, and longer follow-up times may be justified.
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###### 

Baseline demographic and clinical characteristics

  Patient demographic data (n=25)        Mean (SD)                                             
  -------------------------------------- --------------- ------------------------------------- ---------------
  Age (years)                            24.32 (5.76)                                          
  Female (n, %)                          20, 80%                                               
                                         **Adapalene**   **Active ingredient**+**Adapalene**   
                                         **Mean (SD)**   **Mean (SD)**                         ***P*-value**
  **Clinical characteristics**                                                                 
  Comedones                              8.72 (7.05)     8.32 (4.85)                           0.625
  Nodulocystic lesions                   0.84 (1.34)     0.56 (1.08)                           0.258
  Total inflamed lesions                 2.96 (2.32)     3.36 (2.87)                           0.327
  Total lesions                          11.48 (7.29)    11.68 (5.71)                          0.797
  ACC grading                            1.56 (0.51)     1.60 (0.50)                           0.205
  PaGA                                   2.52 (0.77)     2.84 (0.80)                           0.073
  PGA                                    2.32 (0.56)     2.44 (0.51)                           0.265
  VAS radiance                           3.04 (1.81)     2.68 (1.90)                           0.145
  **Skin biophysical properties**                                                              
  Transepidermal water loss (g/m^2^/h)   12.55 (5.84)    13.85 (6.62)                          0.112
  Skin hydration (corneometer unit)      45.17 (9.31)    45.37 (9.65)                          0.888

**Abbreviations:** ACC, Acne Consensus Conference; PaGA, patient's global assessment; PGA, physician's global assessment; VAS, visual analog scale.

###### 

Efficacy and skin biophysical properties

                                         Adapalene              Active ingredient+adapalene
  -------------------------------------- ---------------------- -----------------------------
                                                                
  **Efficacy**                                                  
                                                                
  Comedones                                                     
   Day 0                                 8.68 (6.57--10.78)     8.40 (6.30--10.51)
   Day 7                                 6.82 (4.70--8.95)      6.55 (4.42--8.68)
   Day 14                                4.62 (2.51--6.73)      4.35 (2.23--6.46)
   Day 28                                4.74 (2.63--6.84)      4.46 (2.36--6.57)
                                                                
  Inflammatory lesion                                           
   Day 0                                 2.99 (2.40--3.58)      3.13 (2.54--3.72)
   Day 7                                 1.83 (1.23--2.43)      1.97 (1.37--2.58)
   Day 14                                1.49 (0.90--2.08)      1.63 (1.04--2.22)
   Day 28                                1.01 (0.42--1.50)      1.15 (0.56--1.74)
                                                                
  Severity of acne (ACC grading)                                
   Day 0                                 1.58 (1.41--1.74)      1.58 (1.42--1.75)
   Day 7                                 1.42 (1.25--1.59)      1.42 (1.25--1.59)
   Day 14                                1.19 (1.02--1.35)      1.19 (1.02--1.36)
   Day 28                                1.02 (0.85--1.18)      1.02 (0.86--1.19)
                                                                
  **Skin biophysical properties**                               
                                                                
  Transepidermal water loss (g/m^2^/h)                          
   Day 0                                 12.32 (10.31--14.33)   14.07 (12.06--16.09)
   Day 7                                 11.54 (9.49--13.59)    13.30 (11.24--15.35)
   Day 14                                11.92 (9.91--13.94)    13.68 (11.65--15.70)
   Day 28                                12.40 (10.39--14.41)   14.15 (12.14--16.17)
                                                                
  Skin hydration (corneometer unit)                             
   Day 0                                 45.11 (42.22--48.00)   45.43 (42.54--48.32)
   Day 7                                 53.36 (50.39--56.32)   53.68 (50.71--56.64)
   Day 14                                54.37 (51.48--57.27)   54.70 (51.78--57.60)
   Day 28                                50.21 (47.32--53.09)   50.53 (47.64--53.42)

**Abbreviation:** ACC, Acne Consensus Conference.

###### 

Safety assessment and Visia score

                             Adapalene                  Active ingredient+adapalene
  -------------------------- -------------------------- ---------------------------------------------------------------------
                                                        
  **Safety assessment**                                 
                                                        
  **Patient report**                                    
  Burning sensation                                     
   Day 0                     0.00 (−0.26--0.26)         0.00 (−0.26--0.26)
   Day 7                     **0.50 (0.22--0.77)**      **1.23 (0.96--1.51)[a](#tfn3-ccid-12-151){ref-type="table-fn"}**
   Day 14                    **0.32 (0.06--0.58)**      **1.30 (0.77--1.30)[a](#tfn3-ccid-12-151){ref-type="table-fn"}**
   Day 28                    **0.16 (--0.10--0.42)**    **0.96 (0.70--1.22)[a](#tfn3-ccid-12-151){ref-type="table-fn"}**
                                                        
  Erythema                                              
   Day 0                     --0.08 (−0.21--0.05)       --0.08 (−0.05--0.21)
   Day 7                     0.16 (0.03--0.29)          0.31 (0.18--0.44)
   Day 14                    0.07 (−0.06--0.19)         0.22(0.09--0.35)
   Day 28                    0.02 (−0.11--0.15)         0.18 (0.05--0.31)
                                                        
  **Physician report**                                  
  Scaling score                                         
   Day 0                     --0.01 (−0.15----0.13)     0.01 (−0.13--0.15)
   Day 7                     0.13 (−0.01--0.23)         0.15 (0.01--0.30)
   Day 14                    0.12 (−0.03--0.26)         0.14 (−0.01--0.28)
   Day 28                    0.37 (0.23--0.51)          0.39 (0.25--0.53)
                                                        
  Erythema score                                        
   Day 0                     −0.02 (−0.06--0.02)        0.02 (−0.02--0.06)
   Day 7                     −0.02 (−0.06--0.03)        0.02 (−0.03--0.06)
   Day 14                    0.01 (−0.05--0.05)         0.04 (−0.01--0.08)
   Day 28                    0.03 (−0.02--0.06)         0.06 (0.02--0.10)
                                                        
  **Visia absolute score**                              
                                                        
  Red area score                                        
   Day 0                     28.72 (26.82--30.61)       28.26 (26.36--30.61)
   Day 7                     29.91 (28.01--31.81)       29.46 (27.56--31.36)
   Day 14                    30.01 (28.12--31.91)       29.56 (27.66--31.45)
   Day 28                    29.09 (27.12--30.98)       28.63 (26.74--30.52)
                                                        
  Spot score                                            
   Day 0                     43.23 (39.21--47.25)       45.58 (41.56--49.60)
   Day 7                     **45.77 (41.72--49.82)**   **48.12 (44.07--52.17)[b](#tfn4-ccid-12-151){ref-type="table-fn"}**
   Day 14                    **44.36 (40.34--48.38)**   **46.71 (42.69--50.73)[b](#tfn4-ccid-12-151){ref-type="table-fn"}**
   Day 28                    **45.29 (41.27--49.31)**   **47.64 (43.62--51.66)[b](#tfn4-ccid-12-151){ref-type="table-fn"}**

**Note:**

*P*-value=0.0020 and

*P*-value=0.0243. Bold values indicate statistical significance.
